Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

Healthy Volunteers Clinical Trial

Official title:

A Randomized, Open-Label, 3-Period, Single-Dose, Cross-Over Study in Healthy Participants to Assess the Relative Bioavailability of AGMB-129 Given as Tablet Formulation Versus the Capsule Reference Formulation and to Assess the Effect of Food on Tablet Formulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06397508
• Other study ID #: AGMB-129-C103
• Status: Completed
• Phase: Phase 1
• Start date: April 2, 2024
• Est. completion date: May 13, 2024

Study information

• Verified date: May 2024
• Source: Agomab Therapeutics NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, open-label, single-dose, randomized, 3-period cross-over, Phase 1 study in healthy adult participants to assess the BA of AGMB-129 tablet formulation relative to that of the reference capsule formulation and to assess the effect of food on the BA of a single oral dose of the AGMB-129 tablet formulation.

A total of 24 participants will be enrolled. Participants will be randomized to 1 of 6 intervention sequences (Williams design) according to a 6-sequence, 3-period design. In 3 sequential intervention periods, each participant will receive 3 study interventions, 1 in each intervention period. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: May 13, 2024
• Est. primary completion date: May 8, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Key Inclusion Criteria:

1. Male or female, between 18 and 55 years old (extremes included) on the date of signing the ICF.

2. Body weight of at least 50.0 kg for men and 45.0 kg for women, and a body mass index (BMI) between 19.0 and 30.0 kg/m2 (extremes included) at screening.

3. Must be in good health based on medical history, physical examination, vital signs, and 12-lead ECG in the opinion of the investigator at screening.

4. Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be =1.5x upper limit of normal (ULN) at screening. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator. Note: Participants with diagnosed Gilbert's syndrome with total bilirubin >1.5 ULN are eligible for the study if AST and ALT are =1.5x ULN.

Key Exclusion Criteria:

1. Known hypersensitivity to AGMB-129 ingredients or history of a significant allergic reaction to AGMB-129 ingredients as determined by the investigator.

2. Positive serology for hepatitis B virus surface antigen (HBsAg) or anti-hepatitis C virus [HCV] antibodies at screening, or history of hepatitis from any cause except for hepatitis A that was resolved at least 3 months prior to the first IP administration.

3. History of or a current immunosuppressive condition, including positive human immunodeficiency virus types 1 or 2 (HIV-1 [2]) antibodies at screening.

4. Current or history of vasculitis, valvular heart disease, or large vessel vascular disease (such as aneurism or dissection) at screening.

5. Any illness, judged by the investigator as clinically significant, in the 3 months prior to the first IP administration.

6. Presence or sequelae of gastrointestinal, liver, kidney (estimated glomerular filtration rate [eGFR] =80 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at screening.

7. History of malignancy within the past 5 years prior to screening, except for excised and curatively treated non-metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of cervix which is considered cured with minimal risk of recurrence.

8. History or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction, e.g., known long QT syndrome or a QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 ms detected on the 12-lead ECG at screening or Day 1 predose. A first-degree atrioventricular block will not be considered as a clinically significant abnormality.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• AGMB-129
Each participant will receive 3 study interventions, 1 in each intervention period

Locations

Country	Name	City	State
Belgium	SGS Belgium	Edegem

Sponsors (1)

Lead Sponsor	Collaborator
Agomab Spain S.L.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax for AGMB-129		From baseline to Day 3
Primary	Cmax for MET-158		From baseline to Day 3
Primary	Cmax for MET-154		From baseline to Day 3
Primary	AUC0-t for AGMB-129		From baseline to Day 3
Primary	AUC0-t for MET-158		From baseline to Day 3
Primary	AUC0-t for MET-154		From baseline to Day 3
Primary	AUC0-8 for AGMB-447		From baseline to Day 3
Primary	AUC0-8 for MET-158		From baseline to Day 3
Primary	AUC0-8 for MET-154		From baseline to Day 3
Secondary	Number of participants with adverse events	To evaluate the safety and tolerability of AGMB-129 in terms of adverse events at every visit	From Screening to Day 5
Secondary	Number of participants with abnormal clinical laboratory values	To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit	From Screening to Day 5
Secondary	Number of participants with abnormal vital signs	To evaluate the safety and tolerability of AGMB-129 in terms of vital signs at every visit	From Screening to Day 5
Secondary	Number of participants with abnormal physical exams	To evaluate the safety and tolerability of AGMB-129 in terms of physical exams at every visit	From Screening to Day 5